Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.

Faes Farma SA is primarily present in Spain and Portugal.

Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.

Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.

Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.

Faes Farma SA is primarily active in the pharmaceutical industry.

The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.

De Faes Farma K/W is 12,46.

De Faes Farma KUV is 2,27.

De AlleAktien Kwaliteitsscore voor Faes Farma is 7/10.

De verwachte Faes Farma omzet is 483,79 mln. EUR.

De verwachte Faes Farma winst is 88,02 mln. EUR.

Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.

Faes Farma keert een dividend van 0,04 EUR uit, verdeeld over 2 betalingen per jaar.

Faes Farma keert 2 keer per jaar een dividend uit.

De ISIN van Faes Farma is ES0134950F36.

Het WKN van Faes Farma is A0MKAC.

De ticker van Faes Farma is FAE.MC.

Binnen de laatste 12 maanden betaalde Faes Farma een dividend van 0,16 EUR . Dit komt overeen met een dividendrendement van ongeveer 4,39 %. Voor de komende 12 maanden zal Faes Farma naar verwachting een dividend van 0,17 EUR betalen.

De dividendrendement van Faes Farma is momenteel 4,39 %.

Faes Farma betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden februari, mei, februari, augustus.

Faes Farma betaalde de afgelopen 24 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0,17 EUR verwacht. Dit komt overeen met een dividendrendement van 4,78 %.

Faes Farma wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Faes Farma van 8-7-2024 ter hoogte van 0,116 EUR te ontvangen, moest je het aandeel voor de ex-datum op 4-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 8-7-2024.

In het jaar 2023 heeft Faes Farma 0,035 EUR aan dividenden uitgekeerd.

De dividenden van Faes Farma worden in EUR uitgekeerd.